Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish

Zhang, Shiru; Pan, Miao; Gao, Ying-Bin; Fan, Ruo-Yue; Bin, Xinni; Qian, Sitong; Tang, Chenglun; Ying, Hanjie; Wu, Jiaqi; He, Ming-Fang

doi:10.1016/j.phymed.2022.154613

Cited by 6 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cordycepin, a type of nucleoside analog, is the major bioactive compound extracted from Cordyceps militaris and has various biological properties, including anti-bacterial ( Jiang et al ., 2019 ), anti-ischemic ( Cheng et al ., 2011 ), and anti-diabetic activities ( Yan et al ., 2023 ). Cordycepin showed potent anti-tumor properties against several cancer types, including liver cancer, lung cancer, and brain cancer, and the involved mechanisms include apoptosis induction, cell cycle arrest, and anti-metastasis ( Hueng et al ., 2017 ; Guo et al ., 2020 ; Zhang et al ., 2023 ). Specifically, cordycepin sensitizes esophageal cancer cells to cisplatin and glioma cells to temozolomide ( Bi et al ., 2018 ; Gao et al ., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Cordycepin Enhanced Therapeutic Potential of Gemcitabine against Cholangiocarcinoma via Downregulating Cancer Stem-Like Properties

Lee,

Na,

Seong

et al. 2024

Biomol Ther (Seoul)

View full text Add to dashboard Cite

Cordycepin, a valuable bioactive component isolated from Cordyceps militaris , has been reported to possess anti-cancer potential and the property to enhance the effects of chemotherapeutic agents in various types of cancers. However, the ability of cordycepin to chemosensitize cholangiocarcinoma (CCA) cells to gemcitabine has not yet been evaluated. The current study was performed to evaluate the above, and the mechanisms associated with it. The study analyzed the effects of cordycepin in combination with gemcitabine on the cancer stem-like properties of the CCA SNU478 cell line, including its anti-apoptotic, migratory, and antioxidant effects. In addition, the combination of cordycepin and gemcitabine was evaluated in the CCA xenograft model. The cordycepin treatment significantly decreased SNU478 cell viability and, in combination with gemcitabine, additively reduced cell viability. The cordycepin and gemcitabine co-treatment significantly increased the Annexin V+ population and downregulated B-cell lymphoma 2 (Bcl-2) expression, suggesting that the decreased cell viability in the cordycepin+gemcitabine group may result from an increase in apoptotic death. In addition, the cordycepin and gemcitabine co-treatment significantly reduced the migratory ability of SNU478 cells in the wound healing and trans-well migration assays. It was observed that the cordycepin and gemcitabine co-treatment reduced the CD44 high CD133 high population in SNU478 cells and the expression level of sex determining region Y-box 2 (Sox-2), indicating the downregulation of the cancer stem-like population. Cordycepin also enhanced oxidative damage mediated by gemcitabine in MitoSOX staining associated with the upregulated Kelch like ECH Associated Protein 1 (Keap1)/nuclear factor erythroid 2–related factor 2 (Nrf2) expression ratio. In the SNU478 xenograft model, co-administration of cordycepin and gemcitabine additively delayed tumor growth. These results indicate that cordycepin potentiates the chemotherapeutic property of gemcitabine against CCA, which results from the downregulation of its cancer-stem-like properties. Hence, the combination therapy of cordycepin and gemcitabine may be a promising therapeutic strategy in the treatment of CCA.

show abstract

Section: Introductionmentioning

confidence: 99%

Cordycepin Enhanced Therapeutic Potential of Gemcitabine against Cholangiocarcinoma via Downregulating Cancer Stem-Like Properties

Lee,

Na,

Seong

et al. 2024

Biomol Ther (Seoul)

View full text Add to dashboard Cite

show abstract

Metastatic brain tumors: from development to cutting‐edge treatment

Tanzhu,

Chen,

Ning

et al. 2024

MedComm

View full text Add to dashboard Cite

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting‐edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood–brain barrier to achieve high intracranial concentrations, including small‐molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

show abstract

Cordycepin enhances the Anticancer efficacy of PD-L1 blockade by modulating the tumor microenvironment of colon cancer

Feng,

Chen,

Gao

et al. 2024

European Journal of Pharmacology

View full text Add to dashboard Cite

Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish

Cited by 6 publications

References 56 publications

Cordycepin Enhanced Therapeutic Potential of Gemcitabine against Cholangiocarcinoma via Downregulating Cancer Stem-Like Properties

Cordycepin Enhanced Therapeutic Potential of Gemcitabine against Cholangiocarcinoma via Downregulating Cancer Stem-Like Properties

Metastatic brain tumors: from development to cutting‐edge treatment

Cordycepin enhances the Anticancer efficacy of PD-L1 blockade by modulating the tumor microenvironment of colon cancer

Contact Info

Product

Resources

About